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Summary 
Anti-double-stranded DNA antibodies are the hallmark of the disease systemic lupus erythematosus 
and are believed to contribute to pathogenesis. While a large number of anti-DNA antibodies 
from mice with lupus-like syndromes have been characterized  and their variable region genes 
sequenced, few human anti-DNA antibodies have been reported. We describe here the variable 
region gene sequences of eight antibodies produced by Epstein-Barr  virus (EBV)-transformed 
B ceils that bear the 3I idiotype, an idiotype expressed on anti-DNA antibodies and present 
in high titer in patients with systemic lupus. The comparison of these antibodies to the light 
chains of 3I + myeloma proteins and serum antibodies reveals that EBV transformation yields 
B cells producing antibodies representative  of the expressed antibody repertoire.  The analysis 
of nucleotide and amino acid sequences of these antibodies suggests the first complementarity 
determining region of the light chain may be important in DNA binding and that paradigms 
previously generated to account for DNA binding require modification. The understanding of 
the molecular genetics of the anti-DNA response requires  a more complete description of the 
immunoglobulin germ line repertoire, but data reported here suggest that somatic diversification 
is a characteristic  of the anti-DNA response. 
S 
Ystemic lupus erythematosus (SLE) is an autoimmune dis- 
order with a wide spectrum of clinical manifestations. 
The glomerulonephritis of SLE is thought to be caused, in 
part,  by  antibodies  to  double-stranded DNA  (dsDNA) 1 
(1-3). Antibodies to dsDNA are unique to this disease. Their 
presence correlates with disease activity and they can be eluted 
from the kidneys of patients with lupus nephritis (1). Recent 
studies have shown that anti-DNA mAbs perfused through 
kidneys in vitro or injected into mice in vivo can lead to glo- 
merular pathology similar to that seen in SLE (4, 5). Anti- 
DNA antibodies are thought to cause disease either by binding 
directly to glomerular basement membrane antigens or by 
depositing as immune complexes in the glomeruli. 
To understand the molecular genetic origin of anti-dsDNA 
antibodies and the structural basis for DNA binding, we un- 
dertook an idiotypic analysis of anti-DNA antibodies. The 
antibodies reported here all bear the 3I idiotype. This idio- 
type is present on K  light chains of anti-DNA antibodies (6). 
High  titered  expression  of 3I +  antibodies  is  present  in 
1 Abbreviations  used  in  this paper:  dsDNA, double-stranded  DNA; R/S, 
replacement to silent; FW, framework. 
"~80% of SLE patients with anti-DNA activity. 3I § Igs are 
deposited in the skin and kidneys of SLE patients indicating 
that  3I +  antibodies  include  a  pathogenic  subset  (7). 
Nonetheless, like other autoantibody-associated idiotypes, the 
3I idiotype is also present on antibodies without DNA binding 
specificity (8, 9). From studies on 3I + myeloma proteins, we 
have hypothesized that in this idiotype system, DNA binding 
is acquired by somatic mutation of germ line variable region 
genes that do not, in their germ line configuration, display 
specificity for DNA. 
Previously, our laboratory has shown that 3I + B cell lines 
derived from lupus patients and from a myeloma patient with 
a 3I + myeloma protein preferentially utilize members of the 
VK1 gene family to encode their light chains (10). To fur- 
ther characterize 3I + Igs and attempt to define the structural 
basis  for  idiotype and  the  motifs contributing to  DNA 
binding, we decided to obtain sequence data from a large 
number of antibodies.  The nucleotide and deduced amino 
acid sequences of eight 3I + Igs produced by B cell lines from 
SLE and myeloma patients are reported. In addition, we re- 
port partial amino acid sequence analysis from several 3I + 
myeloma proteins and a consensus sequence from polyclonal 
3I + anti-DNA antibodies isolated from the serum of a SLE 
patient. The mutational analysis of these antibodies is at- 
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of idiotype-positive anti-DNA antibodies and the role of an- 
tigen in eliciting  their production. 
Materials and Methods 
Generation of  Anti-DNA Antibodies.  Anti-DNA antibodies were 
generated by EBV transformation of bone marrow (myeloma pa- 
tient), peripheral blood, or spleen cells (three SLE patients) as de- 
scribed in detail previously (10). Isotype and idiotype determina- 
tions were made by ELISA and have been described previously (10) 
(Table 1). 
RNA  Preparation.  Total  RNA  was  prepared  from  10  s cells 
using guanidinium thiocyanate extraction (10). Determination of 
variable region gene utilization for both heavy and light chains 
has been described (10). 
Cloning  the  Productively Rearranged V~: and  1I,  Genes.  CK 
primer 5'GTTCCAGATTTCAACTGCTCY, C# primer 5'GAG- 
GGGGAAAAGGGTTGGGGC3', C3/primer 5'GCCAGGGGG- 
AAGACCGATGGY,  or Ccr  primer 5'GGCTCAGCGGGAAGA- 
CCTTGY was used to reverse transcribe 10 #g of total RNA into 
cDNA. The complete PCR has been described in detail elsewhere 
(10). The primers for the V. and VK regions were oligonucleo- 
tides specific for the 5' leader sequence or first framework sequences 
of each appropriate variable region gene family. VK1, 5'ACATG- 
AGGGTCCCCGCTCAG3', or 5'GACATCCAGTTGACCCAG- 
TC3'  (H2F,  I-2a);  V~r  5'ATGGAAACCCCAGCGCAGCT3'; 
V,1, 5'CAGGTGCAGCTGGTGCAGTC3; (IC4) V,3, 5'CAGG- 
TGCAGCTGGTGGAGTCT3';  V.4,  5'CAGGTGCAGCTGCA- 
GGAGTC3'; and V,5,  5'ATGGGGTCAACCGCCATCCT3'. 30 
PCR cycles were performed under the following conditions: denatu- 
ration (94~  1 min), annealing (48~  1 rain), and extension (72~ 
3 rain). Further amplification of PCR products was performed after 
elution of  DNA from a 2.5% low melt agarose gel (NuSieve GTG; 
FMR, BioProducts, Rockland, ME). The amplified products were 
blunt end ligated to either dephosphorylated pGEM or pBluescript 
SK §  Competent DH5 cells (pGEM) or XL-1 Blue cells (Blue- 
script SK*) were transformed with the ligation mixtures. DNA 
was prepared from VK-positive colonies and DNA was sequenced 
using Sequenase (Amersham Corp., Arlington Heights,  IL) (11, 
12). Some PCR products were directly sequenced,  as previously 
described  (10). 
Cloning of Germ Line Vgl Genes.  Complete EcoRI digests of 
genomic DNA from bone marrow-derived cells of patient HIC 
were cloned into the EcoRl site of Charon  16A (13) and >106 
phage were screened  using a  VKl-specific DNA  coding region 
probe  as  described  elsewhere  (10).  VKl-positive  phages  were 
purified, subcloned into pGEM, and sequenced using the standard 
Sequenase protocol. 
An MboI partial library from spleen cells of patient DIL was 
constructed in Charon 40.  More than  106 phage were screened 
using the VK1 probe described  above. VKl-positive  phage were 
purified, subcloned into pBluescript, selected with a CDR1 oligo 
5'TTAGTAACTATTTAAATTGG3',  and sequenced  as above. 
Myeloma Sera and SLE Sera.  Myeloma were obtained from three 
sources: Dr. Jean-Louis Preud'homme (Poitiers, France), Dr. Peter 
Wiernick (Albert Einstein College of Medicine, Bronx, NY), and 
Dr. Alan Solomon (University of Tennessee, Knoxville, TN). SLE 
serum from one patient was obtained from the clinic at the Bronx 
Municipal Hospital Center. All were screened for 3I reactivity by 
ELISA and dsDNA binding by Western blot analysis (14) (Table 2). 
lgGfrom SLE Patient.  Purified IgG was obtained from serum 
by molecular sieve chromatography using a Sephacry1300 column 
(Pharmacia  Fine Chemicals,  Uppsala,  Sweden) with 0.01 M Tris, 
0.001  M  EDTA,  0.5 M  NaC1,  pH  7,  as running buffer.  DNA 
binding antibodies were precipitated with dsDNA and then 31- 
reactive antibodies were obtained by affinity chromatography (6). 
NH2-terminal Amino Acid Sequences of 3I-reactive Light Chains 
from Myeloma Proteins and SLE Serum.  10 ml of sera from each 
of six patients with a 3I-reactive myeloma protein was precipitated 
with 50% ammonium sulphate and the precipitate resuspended and 
displayed on an analytic IEF gel to determine the isoelectric point 
of the myeloma protein. The myeloma protein was then purified 
by preparative IEF. The purity of each protein was determined by 
SDS-PAGE and analytic IEF gel. 
Myeloma proteins and 3I + serum antibodies were reduced using 
6 M urea and either 0.01 M dithiothreitol or 2% mercaptoethanol 
in 0.1 M Tris, pH 8.0, at 37~  for 2 h and alkylated using 0.05 M 
iodoacetic acid (15). Heavy and light chains were separated by gel 
filtration on a Sephacryl 200 column (Pharmacia  Fine Chemicals) 
in 0.05 M Tris, 0.001  M EDTA, 0.1 M NaC1  1% SDS, pH 6.8. 
The alkylated light chains were subjected  to automated sequence 
analysis (B890M; Beckman Instruments, Fullerton, CA). The ini- 
tial protein loading was between 5 and 10 nmol and was sequenced 
in the presence of 2 mg polybrene. The amino acids were identified 
by two independent reverse phase HPLC methods (16). Protein se- 
quences were then compared with known Ig light chains from the 
Dayhoff Protein Sequence Bank and were analyzed for the pres- 
ence of invariant  residues  of the VK families (17). 
Results 
3I § Light Chains of EBV-transformed B  Cell Lines.  The 
molecular characterization of anti-dsDNA antibodies neces- 
sitated that we obtain nucleotide sequences of the light and 
heavy chain variable regions of the 3I + antibodies produced 
by EBV-transformed cell lines. Six of the monoclonal lines 
and  one  previously  reported,  2A4,  (18)  express  a  V~I- 
encoded light chain (Fig.  1).  While there is a high degree 
of homology among the VK1 sequences, it is not so striking 
Table  1.  EBV-transformed  Cell Lines 
DNA 
Cell line  Patient  Isotype  binding  VK  V, 
III-3R  DIL (SLE)  /z  +  1  3 
III-2R  DIL  #  +  1  1 
IC4  HIC (myeloma)  #  +  1  4 
I-2a  DIL  7  +  1  3 
1X7RG1  DIL  cr  +  1  3 
2A4  HIC  y  +  1  4 
R3.5H5G  RIO  (SLE)  7  -  1  1 
1I-1  DIL  /x  +  3  5 
H2F  HER (SLE)  ~/  +  4  3 
Characteristics of EBV-transformed  B cell lines denoting patient origin, 
isotype of" antibody produced, DNA binding, and Vg and V. family 
utilization. 
1640  Antibodies  Bearing an Anti-DNA-associated Idiotype III-3R  (p) 
III-2R  (u) 
It4 (p) 
I-2~  (x) 
lXTRGI  (a) 
~4  (v) 
R3.SH.SG  (v) 
III-3R 
III-2R 
IC4 
l-2a 
lXTRgl 
2A4 
R3.51t5G 
CDRI 
1  10  ZO  30 
GACATCCAGATGAC  C  CAGT  CT CCATC  CTCCCTGTCTGCAT  CTGTAC.q~d~GACAGAGT  CACCATCAC~GCCAGGCGAGT~CKFTAGI 
.....................................................................  G ...........  G  .....  -C 
....................................  T ................................  AA  .......  A  ........ 
.........  T- .................  T ......................................  -A~---C .............  -A 
..........  C  .....  T ...........  A .......  T .....  T ......................  T-G ..........  ~  .....  -C 
---C--A  .................  -A ......  C .........  T .......  C  ...............  -G---A  ......  AG  .....  AC 
...................................................................  -G---A  ......  AG----G--C 
CDII2 
31  40  50  60 
AACTATTIN~qTIGGTATCAGCAGAAAC~CC  CTAAGCTCCTGATCTACGATGCK[CCAATCTGGAAACAGGGGTCCCATCA 
--T .....  --GCC ........................  TT .................  T-C ......  C-T--C--T  .............  T 
---G  ..................  A ...........................................  T .....  --G  ............ 
--T .....  --CC ...........  A ...................  AG  ..........  TCC  .......  C-T--C---GT  .....  A--C--- 
--T .....  --GCC----T ...........................  TC---AT-G-  -TA--C  ......  G-T- -C- --GT ........... 
-GG-T ................................................  T-G ......  ,-,--,--,,---,--,-,--- 
-G--T----C-  ..............  -G  .........  --G  .....  -A ..........  CT-C .....  -G-T--C-G-GT  ........... 
III-3R 
II I-L;'R 
IC4 
l-2a 
IXTRGI 
2A4 
R3. SHSG 
III-3R 
III-L~R 
IC4 
l-2a 
IXTR81 
2A4 
P.3.5145G 
61  70  80  90 
AGGATCAGTGGAAGTGGATCCGGGA~ACTrrCACCATCAGCAGC  CTGCAGCCTGAAGATA1XGCAACAIATTACTGTCAA~ 
C--T ......  C  .......  -1"  ...........  C----C ............................  G  .......  T ............  A-- 
---T-  .....  -G  .......  T ...........  C ....................................................... 
---T----C--C  ........  T ........  A--C---e----A----T  ..............  -G---T  .......  T .............  -~q 
---T----C--C  ........  T ...........  C---C .........  A--A ...............  T .......  T ........  C  ..... 
--44  ....  C  ........  T .......  -G--C---C  ..........  A--T .....  A------G---T  .......  T--C  ........... 
---T  ......  C  .....  T--T--A  ........  C---C  .............  T .....  A- .......  T .......  T--C ........... 
CDR3 
91  95 
TATGATAATCTCCCTCTCACT'rFCGGCGGAGGGACC.qAGGTGGAGATCAAACGTCGT  ( JK4 ) 
---A-C--G--GC----CCGAGTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGT ( -N-Jgl  ) 
.......  C  ......  CT~CGGOGGAGGGACCMGGTGGAGATCAJLACGT  ( JK4 ) 
CT-AT- -G-TA- - ~CTTCGGCGGAGGGACCAAGGTGGAGAT~CGT  ( -N  - JK4 ) 
---C---G4AT--COGGACTTrFGGC~C~TGGAGATCAAACGT  (-N-aK2) 
AG-T---G-AC--  - - CCGGAC.q~~TGGAAAT~T  ( - N-,]ic2 ) 
AG-T-C-G-AC--TGTACACTTFTGGC  ~CCMGCTGGAGAT  ~CGT  ( JK2 ) 
Figure 1.  Nucleotide sequences of seven human Vxl 
31 + light chain variable regions. The sequence  of 2A4 has 
been previously reported (18) and is included for com- 
parison. 
H-1 (p) 
CDR1 
1  10  20  30 
GAAATAGTGATGACGCAGTC~CCAGCCACCCTGTCTGTGTCTC~AGGGGAAAGAGCCACCCTCTCCTGCAGGGcCAGTCAGAGTG]XAAC 
CDR2 
40  50  60 
AGCAAC~AGCCTGGTACCAGCAGAAAC~TGGCCAGGCTCC~CCTCATCTATGGTGCATCCACCNg~G~CACTGGTATCCCAGTC 
70  80  90 
AGGATCAGTGGCAGTGGGTCTGGGACAGAGT~CACTCTCACCATC~GCAGC~]CAGTCTGAAGA]TTTGCAGTTTK~ACTGT~ 
CDR3 
95 
TATAATAACTGGCCTCTGTGGACGTTCGGC~CAAGGTGGN~qTCAAACG(-N-JKI) 
Figure 2.  Nucleotide sequence of the II-1 light chain 
variable region. 
H2F  (v) 
CDR1 
10  20 
~GACAT~CAG13~D~CAGTCT~CAGACT~CTGGCTGTGT~T~TGGG~GAGAGGG~CA~CAT~AA~TGCAAGTCCAGCCAGAGTGTT~T~A 
CDR2 
30  40  50 
TACAGC[C~TTACTTM~TAC~C~CTCCTAP3~CW=CTC~q~ACT~CATCTACC~ 
60  70  80 
GAATCcGGGGTCCCr~(~A]TCJ~G~TL~H]GGAcAGAT~TCACTCTCACCATCP~cj~GCCTr~d%qG(]CTGAJ~ATGTGGCA 
CDR3 
90  95 
GTTTATTACTGTCAGCAATATIATAGTACTCCTCGAN3GTTCGGCCAAGGGAC  CAAGGTGGAAAIC.AAA  ( - N - JK 1 ) 
Figure 3.  Nucleotide sequence of the H2F light chain 
variable region. 
FW1  CDR1  FM2  CDR2 
III-3R  DI(MTQSPSSLSASVGDRVTITC  Q/LSQOISNYLN  WYQQKPGKAFgLLIY  DASNLET 
[II-2R  .......................  R---G  .....  A  ........  V .....  A--T-QS 
IC4  .......................  -1"  .....  K ......................  R 
l-2a  ---L  .....  F .............  R  .....  R---T  ..........  V---  P--T-QS 
1X7RG1  ---I-H  .................  R----G .....  A  -F ........  S-L-  NP-S-Q$ 
2A4  -LK ........  P .....  T .....  R---S-NRF  ................  G--S-QS 
R3.5HSG  .......................  R---S-GSF-H  .......  -G-----S  A--S-Q$ 
II-]  E-V .....  AT--V-P-E-A-LS-  R---SVNSN-A  .......  Q--R ....  G--TRA- 
H2F  ---L  .... D-mAV-L-E-A--N-  KS--ZNNK---T  .......  OP  .....  W--TR-$ 
FM3  CDR  3 
GVPSRISGSGSGTDFTFTISSLQPEDIATYYC  QQYDNLP 
.....  F .........  L .........  V .....  QKYNSAP 
.....  F--G- ......................  QQYDTLP 
.....  F .......  E--L--!  ......  F .....  QQLISYP 
.....  F ..........  L--NN .....  F .....  QQYHSYP 
-FS--F  .......  E--L--R  ......  F .....  QQSYSTP 
.....  F ..........  L .........  F .....  (~QSYSTL 
-I-V  .........  E .........  S--F-V---  QEYNNMP 
---D-F  .........  L ......  A--V-V---  QQYYSTP 
Figure  4.  Derived  amino  acid  se- 
quences of3I + VK genes showing con- 
servation  of  sequence  in  framework 
regions. H2F has a six-amino acid in- 
sertion in CDR1  between the gluta- 
mine and the asparagine  residues.  *A 
six-amino  acid  insertion  in  CDRI: 
SVLYSS. 
as to suggest a common germ line gene. One cell line, II-1, 
expresses a VK3-encoded light chain (Fig. 2). The remaining 
line, H2F uses a Vx4-derived light chain (Fig. 3). The V-J 
junctions of each of the five rearranged lines from patient 
DIL and of the two lines from patient HIC differ, indicating 
that the B  cells  within each set are not donally related. 
The  deduced  amino  acid  sequences  of  the  VK1  light 
chains reveal conserved framework (FW) regions (Fig.  4). 
1641  Manheimer-Lory  et al. FH1  CDRI  FM2 
Vkl  IMIt  O  1QI4TQSPSSLSASVGORVT  I TC  I~Ill)ALA  MY(~IQPGKAPKLLLH 
SOil  ......  F  ............  S  ...... NVYTFL- .............  IY 
~OU  A-  ...................  -II  ....  D-RND-G  ............  ly 
?  ...............  E-A--S-  ....  SVS-YLT/a  -T--- 
Vk3  ~  E*VL-Q--Gt--A-P-E-At LSS  -A-sDVD 
Tlgf  E-V  .....  AT--V-P-G-A-LSC  ~-LA  SYQQ~P--e 
HIs  -LV  .....  AT--V-P-QTA-LSC  NL~SSDLV  14Y----GSN~LLI 
F..~RLIIR 
---g-EG 
G 
Figure 5.  Partial protein sequences of the light chains 
of six 3I + myeloma proteins and the light chains of3I + 
anti-DNA antibodies purified from the serum of an SLE 
patient (SNA). Lower case letters denote probable amino 
acids. 
This is especially true for FW2.  Interestingly, the FWs of 
the VK3- and the VK4-encoded light chains are also highly 
homologous to  the  V~:I protein  sequences,  providing a 
potential explanation for their 3I reactivity. The partial pro- 
tein sequences of the 31 + myeloma proteins are remarkably 
similar to the deduced amino acid sequences of the 3I + an- 
tibodies (Fig. 5). Similarly, the consensus sequence of the light 
chains of 3I + serum anti-dsDNA antibodies from the lupus 
patient, SNA, exhibits very strong homology to the light 
chains of the myeloma proteins and to the predicted amino 
acid sequences of the light chains of the EBV-transformed 
lines (Fig. 5). The analysis of these primary amino acid se- 
quences reveals many regions of homology, yet no unique 
region that might represent the 3I + idiotope. 
All the antibodies except R3.5HSG bind dsDNA. Many 
DNA binding antibodies and other DNA binding proteins 
are enriched for arginine, asparagine, and glutamine residues. 
In anti-DNA antibodies, these residues are present in CDRs 
and presumably are contact residues for antigen (19-23). Here 
we find an unusually high number of these residues in CDR1. 
A random sampling of VK1 light chains shows that on av- 
erage 2.8 such residues are present in CDR1 (17). The light 
chains of the eight dsDNA binding antibodies reported here 
contain an average of 3.75 (range, 3-5). The R3.5H5G anti- 
body is the only antibody that does not exhibit any specificity 
for dsDNA and it possesses only two such residues in CDK1. 
Although most of the myeloma proteins also bind dsDNA 
(see Table 2),  the  incidence of arginine,  glutamine,  and 
asparagine residues in the myeloma proteins is not so striking 
as in the antibodies from the EBV-transformed  B cell lines. 
Comparison of  Expressed 31Sequences to Their  Putative  Gennline 
Genes.  The human VK1 gene family is the largest  of the 
four g gene families, containing '~30 genes (24-26).  Our 
previous study of the 2A4 cell line revealed ,,~45 nucleotide 
differences between the most homologous VK1 germ line 
gene and the 2A4 light chain nucleotide sequence, suggesting 
that no published VK1 gene was the germ line gene tem- 
plate for 2A4 (18). This observation prompted us to con- 
struct genomic libraries from both the lupus patient DIL and 
myeloma patient HIC with the hope of obtaining new Vgl 
genes that might be the germ line genes from which our 
expressed antibodies are derived. 
We screened an HIC bone marrow library and a DIL spleen 
library  with  a  VK1  probe  and  isolated  >30  clones  hy- 
bridizing to a Vgl fragment (10). To identify those VK1 
genes that had not been previously reported and that might 
be the template for our 3I + antibodies, we screened the VK1 
clones with an oligonucleotide  probe highly homologous to 
the CDR1 sequence of two of the three IgM antibodies. This 
CDR sequence was not present in any previously reported 
VK1 gene and so was likely to identify new VK1 genes in 
our libraries.  Using this probe, we isolated  from the HIC 
library two new functional germ line genes and one pseu- 
dogene, as well as  two new pseudogenes from the DIL 
library.  The germ line gene DILpl is the only one of the 
genes we cloned with strong homology to any of the 3I + 
sequences reported here. (Fig. 6). This VK1 gene is quite un- 
usual;  codon 88,  GGT,  encodes glycine,  whereas  all  VK 
genes reported to date encode cysteine at this codon. As shown 
in Fig. 1, all the expressed 3I § light chain variable regions 
encode cysteine at codon 88 (TGT). 
We then compared the light chain nucleotide sequences 
of the VK1 3I + antibodies to the DILpl gene or to the most 
homologous germ line sequence available in the literature 
(Table 3). The III-2R IgM line derived from DIL is the most 
homologous  to DILpl, differing by 17 nucleotides. Two others, 
I-2a and 2A4, are more homologous to DILpl than to any 
other reported VK1 gene but differ by 32 and 37 nucleotides, 
respectively  (Table 3).  Three VK1 cell lines,  III-3R,  IC4, 
and IX7RG1, show most homology to the germ line gene 
HK137 (Table 3). In fact, the III-2R line is also more homol- 
ogous to HK137, differing by 15 nucleotides, than to DILpl; 
however, it displays more homology in FW regions to DILpl 
than to HK 137 (25, 27). The VKI sequence from the non- 
DNA binding R3.5H5G cell line is most homologous to 
the germ line gene b' (Table 3). 
Calculation of amino acid replacement to silent changes 
(R/S) (Table 3) indicates that almost all the V~:I antibodies 
Table  2.  31 + Myeloma Proteins 
Protein  VK gene.family  DNA binding 
MAR.  V~I  - 
SCH  VK1  + 
GOU  VK1  + 
BEN  V~3  - 
TEN  V~3  + 
HIC  V~3  + 
Characteristics of 3I+ myeloma proteins including Vtr usage and DNA 
binding. 
1642  Antibodies Bearing an Anti-DNA-assodated  Idiotype 1  10  ~0  3O 
r 
(:St* 
31  40  "SO  60 
AG'TTAT'rTAMI19GTA~CCTAAGCTCCTGATCTATAh"i~aCATCC4Al"13rGCAATCIGGAGT((~,ATCT 
6).  70  80 
~T~TI'rCAr 
91  N 
&'T[ACMIQga:Cl 
Figure 6.  Nucleotide  sequence of the VK1 germline  gene DILp1. 
have  an  R/S  ratio  in  the  CDRs  that  is  >2.9,  the  ratio 
predicted by random mutation. If III-2R is presumed to de- 
rive from the DILpl germ line gene, then only 1X7RG1 shows 
a lower than random R/S ratio in the CDRs. All have an 
R/S ratio <2 in FW regions, suggesting that there may be 
some pressure  for conservation of FW residues.  A  similar 
low R/S ratio in FW has been demonstrated in antibodies 
to foreign antigen (28). 
The VK3-rearranged  gene encoding the II-1  light chain 
shows 98% homology with an autoantibody encoding germ- 
line gene, VK328 (29). Although Vg328 is often used to en- 
code rheumatoid factors,  II-1 has no rheumatoid factor ac- 
tivity (data not shown). Both the base pair substitutions in 
the CDR regions lead to replacement changes, hence,  the 
R/S ratio is 2/0,  although the total number of mutations 
is too few to deduce antigen selection. The R/S ratio in FW 
regions, 2:1, is consistent with random mutation and the ab- 
sence of selective pressures  (Table 3). 
H2F, which is encoded by a VK4-rearranged  gene, shows 
a 98% identity with the only reported VK4 germ line (30). 
The three nucleotide changes in the CDRs lead to a single 
replacement substitution, and three nucleotide substitutions 
in the FWs (two in one codon) account for two amino acid 
changes (Table 3). 
Analysis of the replacement mutations can provide infor- 
mation regarding the selective forces driving the immune re- 
sponse,  and the structural basis for DNA binding. (Tables 
4, 5, and 6). Table 4 displays the amino acid changes of three 
cell lines relative to the DILpl germ line gene. In CDR1, 
cell lines 2A4 and I-2a acquire an arginine or asparagine  at 
residue 30. Cell lines III-2R, 2A4, and I-2a acquire an argi- 
nine or asparagine  at residue 31  compared to the DILpl- 
encoded sequence (Table 4). It is important to note that two 
of the lines,  III-2R and I-2a,  lose an asparagine  at residue 
34, so only 2A4 and I-2a show a net accumulation of argi- 
nine or asparagine  in CDR1. All three lines presumptively 
encoded by DILpl lose  an asparagine  in both CDR2 and 
CDR3 at residues 53 and 93 as well as an arginine at residue 
90. The arginine is replaced by glutamine or lysine, two ad- 
ditional  amino  acids  implicated  in  DNA  binding.  The 
asparagines, however, are replaced by serine or threonine, and 
are, therefore, replacements that might decrease affinity for 
DNA. III-2R acquires an asparagine at residue 92 in CDK3. 
The 3I + light chains possibly encoded by the HK137 gene 
are  similarly analyzed in Table 5.  III-3R and IC4 acquire 
an asparagine  at residue 34 in CDR1.  In CDR2,  IC4 and 
III-3R acquire additional asparagines  at residue 53; IC4 ac- 
quires a second arginine at residue 56, and 1X7RG1 acquires 
an asparagine  at residue 50.  In CDK3, three lines,  III-3R, 
1X7RG1, and IC4, lose a glutamine at residue 90, although 
III-3R acquires asparagine at residue 93. The sequence of the 
R3.5H5G antibody shows a loss of an asparagine  at residue 
Table  3.  Comparison of VK Sequences to Most Homologous Germ Line Gene 
R/S ratios 
FWs  CDRs  R/S per domain 
Germ line  Percent 
gene  Cell line  homology  Total  R  S  Total  R  S  FW1  FW2  FW3  CDR1  CDR2  CDR3 
DILp1  III-2R(#)  96  8  3  5  9  9  0  1:0  1:0  1:5  3:0  2:0  4:0 
2A4(3/)  87  25  13  12  12  11  1  5:2  2:0  6:10  5:0  2:0  4:1 
I-2a(7)  89  19  8  11  13  12  1  1:0  3:2  4:9  5:0  2:0  5:1 
HK137  III-3R(#)  91  13  5  8  13  10  3  0:1  2:1  3:6  3:2  4:1  3:0 
IC4(#)  92  10  5  5  13  12  1  0:3  2:2  3"0  5:1  4:0  3:0 
III-2R(#)  95  10  4  5  5  3  2  0:2  3:0  1:4  0:1  1:0  2:1 
1X7RGI(c~)  95  9  5  4  6  3  3  2:2  1:2  2:0  0:1  2:0  1:2 
b'  R3.SH5G(7)  92  11  3  8  11  8  3  1:1  2:2  0:5  4:1  0:1  4:1 
VK328  II-1(/~)  98  3  2  1  2  2  0  0:0  0:0  2:1  1:0  0:0  1:0 
VK4  H2F(7)  98  3  3  0  3  1  2  3:0  0:0  0:0  1:2  0:0  0:0 
Replacement (R) to silent (S) ratios in the light chains of the 3I + antibodies. The ratio of mutations that result in an amino acid replacement to 
those that are silent are tabulated for the FWs and the CDRs. 
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III-2R 
R3.SH5G 
II1-2R 
R3.SHSG 
III-2R 
R3.SHSG 
III-2R 
R3.SHSG 
CDR1 
1  lO  ZO  30-- 
- AGGTGCAC~TGGT(~CAGTCTGGGGCT~TGAP~GAAGCCTGGGTCC  TCGGTA/~GG TCT(;CTG~CTTCTGG~GGCACCTTC~T~ATACT 
C  ............................................  G----A--G  ...............  A ........  TA  .......  GTC6CC--CTA- 
CDP~ 
4O  5O  60 
AT  ~AGCTGGGTGcGACAGGC~TCq?~A~GAGTGGAT(iGGAAGGATCATGC~TA~C~TTGGACTAGCAAATTACGcA~TT  C  CAC-GGC 
G-~CA  ....................  G  ........  C-A  ........  TT  ......  AC- --.-A,-AG---TG-CA---CC--T-  - - -T--GC--T ...... 
70  80  90 
AGAGTCA~AT~A~GCGGACAAAT~CAC~AGCACAGC~TACAT~iC~AG~TGAGC'AGC~T~TGAGGACAC~aGCCGTGTATTACT~TGCGAGAGAT 
--G-----C--G---AG  .....  CG----TC ................  A .................  C--C ...........  T ...............  TC- 
CCOGATTATEffTTG~GGGAGCGACAACTGBITCGACCCCTGG6GC~CCCTGC TCATCGT  CT  CCTCA 
- - - CTCACIGGTGAC(;CCCGTGGGCTACTITGACTI;CT~CCCTGGTCACCGTCT  CCTCA 
CDR1 
B  z  lo  2o  30 
IlI-gR  ~T~CAGC~GGTC~GAGTCTGc~C~GGAGGCT~G~CCA~CCTGGGGGG~CC~GAGA~TCTCC~GT~CAGCCTCGGAT~CACC1TT~T~CTAT~G 
]  -2A  ........................... g ..............  A-  ......................................  C---TC--C--CT-- 
lXTRG1 ~  .................................  A  ..................  C  ..........................  T---C----C----A-C- 
H2F  .................................  A .......  A .........................................  C-- -GA~--CTAC- 
CDR2 
40  50  6O 
l l 1-3R  AGCTGGGTC  CGC  CAC-~CT  CC~CTGGAGTGGGTGGCCAACATAAAGCAAGATGGAAGTGAGAAATACTATGTGGACTC TGTC.ff~AC.~IGCC,  G 
I-2A  -CA  .....................  C  ....................  ATn'---TCATTG- -G  .....  CAGTC  ........  CA  .....  C  .......... 
IX7RG1  ---AT .....  T ....................  A ...........  TT-AT-T-CT-GTAGTAG- --T- --ACC-TG-----C-CA--T  ............ 
H2F  ........  A ..................................  TT-AT-~--T-GTAGTCG---T - - -ACC-T  ......  C-GA  ............... 
70  80  90 
lll-3R  ATTCACCAT CT  CCAGAGACAACGCCAAGAACTCACTGTATCTGCAAA1T~e~ACAGCCTGAGAGCCGAGGACACGGCOG  TGTAI-IACTGTGCGAG.AGGJ~ 
I-2A  --C ................  "13-  ........  A-G ...............  --G  ............  T ...........  T--A ..............  TCCG 
[X7RG1  ..........................................................................  T--T~---T  ......  A----A 
H2F  ................  -g  ............................................................................  GA 
IlI-3R  GGATGTGGGAGAC~TGGTT  CGGGGAGT  CC  CCGC  CCTTTGACTACTGGGGCCAC.~G/~CC  CTGG  TCACOGTCTCCTCA 
I-2A  6GGAAAGTGGAGAJ~TGGGAGCTCCCT  TI~GACTACTGGGGCCAGGGAAC  CCTGGTCA  CCGTCTC~'TCA 
IX7RG1  TCTGACTACGGAC  GTCTAC'IGGGGCCAC.q?.~d~CC  CTTGTCAC  CGTCTCCTCA 
H2F  TCTGTCTfATGACAGN~C  TACTTTGACTAC16GC.~CCAGGC.~ACCCTGGTCACOGT  CTCCT  CA 
C  1  lid  20  30 
IC4  C~TG~AGCT~TCGGGCCCA~CTc~iTGAAG~TT~GGA~C~CTGTCCCTCAC~T6CAC~GTC~CTG~TGGC]CCATCAGT 
2A4  ............................  -G  ..............  AC  ..................................  T ........  C 
CDRI  CDR2 
50  60 
]C4  ~T  "i'ICTACTGGAIGCTGGATCCI~ICAGT  CCC~CTGGAG(GGATTGG6TATATCTATTATACTGGGAG  CACCAAT 
2A4  ---C.~IAP.T-A ..................  T---C--G-C  ..............  -AG-C  ......  CG----G--ACC-G  ....  A--T---G 
7O  8O  90 
IC4  TATAACC CCT  CCCT  CAAGAGT  CGAGT  CACCATAT CAGTAGACATGT  CCAAGAACCAG~I CTCCC TGAAGC  TGATCTC  TCT~ACCGCTGCG 
2A4  --C  .......................  G-  ........  k ......  C  ............  A ................  G----G .......  C--A 
IC4  GAGACGGCOG'~TATTACTGTECGAG.~Tr CTGGCAGCGCCTGGCCCC~e~USITI'GACTACT~C~CCCII~TCACOG  TC 
2A4  ..........................  -GACT  CTATIM,~,.4~GGAGATT~T CGGGGACCC  CGAGCTAAGGGCCAGGGCTACGGTATGGAC 
IC4  Tr 
ZA4  TCTGGC..~CC,  AP.C,~C~CCAC'GGTCACCGTC  TCC  TCAG CC 
COR1 
D  1  zo  ~o  3o-- 
If-1  GAGGTGCAGCTGGTBCAGT CIEGAGCAGAGGTGAAAAAGCCGGGGG~t CT  CTGAAGATCTC  C  TGTAAGGGTTCTGGATACAGC ~CCTACT~ 
COP.,? 
40  50  60 
ATCGGCTGGGTGCGCCAGATECCCGGGA/~CCTGGAGTGGATGGGGA(;CGT  CTATCCTGGTGACTCTGATACCA~TAC~C  C  CGTCC~C~ 
70  80  90 
CAGGTCACCATCTCAGC~TGCATCAGCACCEICCTACCTGCA~TGGAGCAGC  CTGA,  AGGCCTCGGACAC~CCATGTATTACTGTGCGAGA~ 
~CTACAACTACGGCTACTTOGACCCCTGGGGCCAGGGAACCCTGGTCACCGTC  TC  CTCA 
Figure  7.  (A)  Nucleotide sequences of Val- 
encoded heavy chains. (B) Nudeotide  sequences 
of Vx3-encoded heavy chains. (C) Nucleotide se- 
quences of VH4-encoded heavy chains. The  se- 
quence of 2A4 has been previously reported (18) 
and is included for comparison. (D) Nucleotide 
sequence of V,5-encoded heavy chain. 
92 in CDIL3 when compared to the sequence encoded by 
the b' germ line  gene  (Table 6). 
Pathogenic anti-DNA antibodies are thought to be cat- 
ionic (31). Among the VK1 light chains, there is no trend 
to acquire a more positive net charge. Although cationic anti- 
dsDNA antibodies are preferentially sequestered in the kidney, 
most of the Vzl  sequences expressed in our panel of anti- 
DNA B cells are more negatively charged than the deduced 
amino acid sequence of the germ line genes. 
Two of the 3I + sequences are not encoded by Vzl genes. 
The II-1 light chain derives from a Vz3 gene. It differs from 
the presumed germ line-encoded amino acid sequence by two 
amino acids in FW regions and two in CDRs (Table 7). The 
expressed antibody reflects the acquisition of an asparagine 
in CDR1 and the loss of a glutamine in CDR3. Similarly, 
the Vz4-encoded H2F light chain differs by only three amino 
acids from the putative germ line template (Table 8).  The 
single substitution in a CDR replaces an alanine with a threo- 
nine. The amino acid substitutions  in II-1 and H2F are too 
few to argue for or against antigen  selection. 
31 +  Antibodies  Are  Encoded by  Four V,  Gene  Families. 
The VH gene segments encoding the expressed heavy chains 
of the 3I + antibodies are derived from four families: V,1, 
V,3,  V.4,  and V.5.  The nudeotide sequences, including 
that of 2A4 (18), are shown in Fig. 7. The predicted protein 
sequences of the heavy chains are presented in Fig. 8. If the 
appropriate germ line genes have all been cloned, our sequence 
data suggest that the heavy chains are also somatic mutants 
of their germline counterparts. Table 9 presents the replace- 
ment to silent substitution ratios in FW and CDR regions 
of each antibody compared to the sequence encoded by the 
most homologous published V. germ line gene. In general, 
1644  Antibodies  Bearing an Anti-DNA-associated Idiotype Table  4.  Comparison of 31  § Vrl Antibodies to DILpI 
Amino 
acid  DILp1  III-2P,  2A4  I-2A 
FW1  2  I  -  L  - 
3  Q  -  K  - 
4  L  M  M  - 
10  S  -  --  F 
12  S  -  P  - 
18  R  -  T  - 
CDR1  25  V  A  A  A 
28  G  -  S  D 
30  S  -  N  P. 
31  S  N  P,  N 
32  Y  -  F  - 
34  N  A  -  T 
FW2  37  lk  Q  Q  Q 
43  V  -  A  A 
46  L  -  --  V 
CDR2  50  S  A  G  P 
53  N  T  S  T 
FW3  58  V  -  F  - 
59  P  -  S  - 
70  D  --  E  E 
76  S  -  R  I 
83  V  -  F  F 
88  G  C  C  C 
CDR3  90  R  K  Q  Q 
91  T  Y  S  L 
92  Y  N  -  I 
93  N  S  S  S 
94  A  -  T  Y 
similar to what was seen in the light chains, there is a lower 
than random R/S  ratio in FW  regions and a  higher  than 
random P,/S ratio in CDP,  s.  When  the actual amino acid 
substitutions are examined, a net accumulation of asparagine, 
arginine, or  glutamine is  seen in five antibodies and a  net 
loss in four (Tables 10-13).  Similarly, four anti-DNA anti- 
bodies show  a net gain in positive charge,  and three show 
a net loss. One anti-DNA antibody shows no change in charge 
and R3.5H5G,  which does not bind DNA,  also shows no 
change in charge. 
CDR3 Regions Differ among Anti-DNA Antibodies.  Fig. 
9 shows that a variety of D  segments are used by these EBV 
lines. In fact,  three lines, III-3R, III-2R, and 2A4, express 
D-D fusions, a previously reported feature of autoantibodies 
(18,  32).  Other lines express D  regions that have yet to be 
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Table  5.  Comparison of 31  + VK1 Antibodies to HK137 
Amino 
acid  Hk137  III-3R  III-2R  1X7RG1  IC4 
FW1  4  M  -  -  I  - 
6  Q  -  -  H  - 
CDR1  24  R  Q  -  -  Q 
25  A  -  -  -  T 
28  G  D  -  -  D 
31  N  -  -  -  K 
34  A  N  -  -  N 
FW2  36  F  Y  Y  -  Y 
43  A  -  V  -  - 
46  S  L  L  -  L 
48  I  -  -  L  - 
CDR2  50  A  D  -  N  D 
51  A  -  -  P  - 
53  S  N  T  -  N 
55  Q  E  -  -  E 
56  S  T  -  -  R 
FW3  62  F  I  -  -  - 
65  S  -  -  -  G 
73  L  F  -  -  F 
76  S  -  -  N  - 
77  S  -  -  N  - 
83  F  I  V  -  I 
CDK3  90  Q  -  K  -  - 
92  N  D  -  H  D 
93  S  N  -  -  T 
94  Y  L  A  -  L 
reported and differ from each other as well as from the reported 
D  region genes. 
J~ usage is also not restricted among 3I + or DNA binding 
EBV  lines,  although J.4  is used in seven of the nine lines 
(Fig.  9).  All J.4 +  antibodies have a single silent nucleotide 
change  from  the  published J,4  sequence  (CAG instead of 
CAA) (33). This change may represent a polymorphism within 
the population similar to what others have reported for J.6 
(34).  As in the light chain sequences, there is no common 
junction evident among antibodies deriving from a single in- 
dividual. We, therefore,  cannot establish any genealogy by 
examining the heavy chain genes. 
Discussion 
Structural analyses of antibodies provide information about 
the basis for both idiotype expression and antigenic specificity. 
Molecular genetic studies can provide insights about the B Table  6.  Comparison of R3.5H5G to b' 
Amino 
acid  b'  R3.5H5G 
FW1  11  V  L 
CDR1  28  G  S 
30  S  G 
32  W  F 
34  A  H 
FW2  43  A  G 
49  Y  S 
CDR3  91  A  S 
92  N  Y 
94  F  T 
95  P  L 
Table  7.  Comparison o./'11-1 to  VK328 
Amino 
acid  VK328  II- 1 
CDR1  30  S  N 
FW3  60  G  V 
62  F  I 
CDR3  90  Q  E 
Table  8.  Comparison Mutations in H2F to  V~4 
Amino 
acid  V~4  H2F 
FW~  3  V  q 
4  M  L 
CDR1  34  A  T 
cell producing  a given antibody and the role that  antigen 
or other selective pressures play in the antibody response. To 
further  our understanding  of potentially pathogenic  anti- 
dsDNA antibodies,  we elected to study a large number of 
antibodies  bearing  the  3I +  anti-DNA-associated  idiotype. 
We also wished to study genealogies of 3I + B cells to corre- 
late changes in amino acid sequence with changes in DNA 
binding. While we were unable to obtain B cell genealogies, 
we have analyzed multiple B cell lines derived from two in- 
dividuals as well as single B lines from an additional two in- 
dividuals. 
We have determined the light and heavy chain variable re- 
gion gene sequences of nine EBV-transformed 3I + clonal B 
cell lines. All except one antibody binds to dsDNA. Because 
elevated titers  of 3I + antibodies  are associated in  SLE pa- 
tients with glomerulonephritis and since we have documented 
that  3I + antibodies  are present  in  the  kidneys of patients 
with SLE, the antibodies that bind to dsDNA are presumed 
to include representatives of a pathogenic subset present in 
a large percent  of patients  with  SLE. 
Previously, we addressed questions regarding general mo- 
lecular characteristics  of EBV-transformed  3I + B  cell lines 
(10). We found that 3I + antibodies were encoded mainly by 
V~I light chain genes regardless of patient  origin.  We be- 
lieve EBV transformation  does not introduce experimental 
bias in creating  this  Vg restriction  for two reasons.  First, 
these lines express light chains with amino  acid sequences 
that  are  homologous  to  the  sequence  of 3I +  polyclonal 
serum antibodies from a SLE patient and to a number of 31 + 
myeloma proteins.  Second, other reports of V~ gene usage 
in EBV-transformed B cells show a variety of expressed VK 
genes (34, 35). It is likely,  therefore,  that the data reflect a 
disease-associated,  as well as idiotype-associated, V region re- 
striction as has been proposed by Shen et al. (36) in chronic 
lymphocytic leukemia. 
We wished to determine if sequence analysis could reveal 
residues  or regions  among  the  VK1, VK3,  and  VK4  anti- 
bodies that  constitute the 3I epitope or that  participate in 
DNA binding.  Our results indicate that the 3I + Vgl anti- 
bodies are closely related on both the nucleotide and the pro- 
tein level.  In fact, the data show strong conservation of se- 
quence  in  FW  regions  among  all  the  antibodies.  This 
conservation is evident in the partial protein sequences of the 
3I + myeloma light chains as well. The greater homology in 
FWs than in CDRs supports the hypothesis that the 3I de- 
terminant(s)  lies within the framework regions of the light 
chain. In general, it has been difficult to map antibody idio- 
types; in the 3I system also,  more definitive analysis  using 
peptide scanning  and site directed mutagenesis  will be re- 
quired  to localize the idiotype. 
Sequence analysis  of anti-DNA  antibodies from various 
mouse strains has led to the hypothesis that the presence of 
particular  amino acids  in the CDRs is associated with the 
ability to bind to DNA. A number of amino acids, including 
asparagine,  glutamine, and arginine, have been postulated to 
interact with the major and minor grooves of dsDNA (19). 
These have been implicated in the antigenic specificity ofanti- 
DNA antibodies.  Amino acid sequence analysis of mouse anti- 
DNA antibodies has led to the interesting observation that 
there is an increase in the number of arginines and tyrosines 
over that of previously sequenced mouse antibodies (20, 21, 
37). It has also been suggested that DNA binding may select 
for arginine  in position  98 of mouse heavy chain  variable 
regions (38).  In the heavy chain variable region of human 
anti-DNA antibodies, tyrosine residues at position 32 and/or 
33 as well as Ser-Thr-Asn-Tyr-Asn  in CDR2 have been postu- 
lated to form the DNA binding pocket in anti-DNA anti- 
bodies (37). 
Our data show that the number of arginine,  glutamine, 
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WI3 
1  I0  20  30  40  50  60  70  80  90 
III-2R  _VQ  LVQSGAEVKKPGSSVKVSCgASGGIFSSYT  I SMVRQAPG(IGLEM4GRII4P  I LG  LANYAQKFQGRVT  I TADKSTSTAYI4E  LSS  LRS  EOTAVYY  CAR 
R3.5HSG  Q  ..............  A  .......  T--Y--VA-YVH  .........  -Q----M-N-NS-VIT--LS  .....  ~4-R-T-I ............  D  ......... 
I[I-3R  _VQLVESGGG  LVQI~GS LR  LSCJMSG  FTF$SYI;$1SMVI~LEMVP/( K  KQOGSEKYYVD  SVKGRFT  I SRDNAKNS  LY L(~NNS  LP~E  DTA~Y~ 
I-2a  ..........  V----R ...............  SP-H  .............  -IF-$LE--SQ--A ......  L .....  S--T  .....  S  ..............  S 
IX?RG1  Q .................  T ........  I--T-S-H  .............  SYTS$$~-~I--A-  ...............................  F--- 
ll2F  ............  K- ...............  D-Y---I  ...........  $'f-SSR--TI--A-  ................................... 
VH4  IC4  QVI~LQESGPGLVKPSETLSLTCI'VSGGS  ISSFYMSgl  RQSPGKGLL~IE'TI  YYTGSINYNPSLKSRVTI S~FS~LISLT~TAVYY~ 
2A4  ...............  Q-  .............  -G-*  ......  pA------G--R-ATS-N  l K  ............  [-T  .........  S-V  ...........  H 
VH5  II-1  EVQLVQSGAEVKKPGESLKI  5CIgGSGYSFSTYHIGMVROMPGKGL~VYI~aOSDITYSPSFQGQVT ISADKCISTAYLQWSSLKASDT~Y~ 
Figure 8.  Derived heavy chain amino acid 
sequences of EBV-transformed cell lines. 2A4 
has a two-amino add insertion in CDR2. *NY. 
asparagine,  and tyrosine residues in CDR1  of the K chain 
variable region is distributed as follows: in the eight DNA 
binding antibodies,  four contain five putative DNA-interacting 
amino acids and four antibodies contain four such residues, 
while R3.SH5G,  the one antibody that  shows no dsDNA 
binding, contains only two such residues (Fig. 4). Addition- 
ally, the total number of asparagine residues in CDRs of the 
entire light chain variable region of the DNA binding anti- 
bodies is higher than in the one non-dsDNA binding anti- 
body. Four antibodies contain four asparagine residues, three 
contain two, and one contains one. R3.SH5G, which does 
not bind dsDNA, encodes no asparagine residues. Examina- 
tion of a random population of previously sequenced human 
V~:I,  V~:3, and  VK4  antibodies  reveals  that  they  possess 
fewer asparagine residues than the 3I + DNA binding anti- 
bodies we report  here  (mean,  1.33;  n,  12)  (17). 
While it has been suggested that tyrosine residues in CDRs 
of the  heavy chain  in  mouse may be significant  in DNA 
binding, we do not find any significant increase in tyrosine 
residues in our set of anti-DNA antibodies.  In fact, R3.SH5G, 
the one 3I + antibody that does not bind dsDNA, contains 
two juxtaposed tyrosine residues within CDR1 of the heavy 
chain. 
In searching the sequences of our antibodies for ATP binding 
site motifs, Gly-X-Gly-Lys-Thr, Gly-(X)4-Gly-Lys-Thr-(X)6- 
Ile/Val, or Gly-X-Gly-X-X-Gly/Ser, we find stretches of Gly 
residues interspersed with Ser residues within FW regions. 
These regions appear,  however, to be conserved among all 
the V  K families and not to be specific for V  regions used 
to form anti-DNA  antibodies. 
While the three-dimensional  structure of a folded poly- 
peptide chain is determined by its primary sequence, similar 
Table  9.  Comparison of V~ Sequences to Most Homologous Germline Genes 
R/S ratios 
FWs  CDRs 
Percent 
Germ  line gene  Cell line  homology  Total  R  S  Total  R 
R/S per domain 
S  FW1  FW2  FW3  CDR1  CDR2 
51P1"  III-2R.(#)  96  3  1  2  8  5  3  0:2  0:0  1:0  1:1  4:2 
H16BR*  III-3R(#)  90  18  7  11  7  5  2  1:4  2:1  4:6  3:0  2:2 
71-4s  IC4(/~)  97  10  7  3  3  3  0  3:0  1:3  3:0  1:0  2:0 
56P1"  I-2a(7)  94  3  3  0  9  7  2  0:0  0:0  3:0  2:1  5:1 
V.26S  1X7RGI(o  0  89  18  8  10  12  10  2  4:2  0:3  4:5  3:0  7:2 
71-2s  2A4(3,  )  92  15  5  10  7  7  0  2:3  2:3  1:4  1:0  6:0 
20P3"  R3.5H5G(T)  94  12  6  6  9  7  2  3:0  1:2  2:4  2:1  5:1 
251s  II-1(/~)  98  4  2  2  5  5  0  1:1  0:1  1:0  2:0  3:0 
V.26s  H2F(~)  90  16  6  10  11  9  2  2:4  1:1  3:5  2:1  7:1 
Replacement (R) to silent  (S) ratios  in the heavy chains of the 3I + antibodies.  The ratios  of mutations  that  result  in an amino acid replacement 
to those that  are silent  are tabulated  for the FWs and  the CDRs. 
* Rearranged gene of fetal origin. 
* Germ line pseudogene. 
S Closest homologous germline gene. 
1647  Manheimer-Lory  et al. Table  10.  Replacement Mutations  in  31 + VH1  Sequences 
Amino 
acid  51Pl  III-2R 
CDR1  33  A  T 
CDR2  50  G  R 
52  I  M 
55  F  L 
57  T  L 
FW3  74  E  K 
Amino 
acid  20P3  R3.5H5G 
FW1  24  A  T 
30  T  V 
CDR1  31  G  A 
34  M  V 
FW2  46  E  Q 
CDR2  57  G  V 
59  N  T 
62  Q  L 
63  K  S 
FW3  85  R  S 
98  T  R 
Table  11.  Replacement  Mutations  in  31 §  V.3  Sequences 
Amino 
acid  VH26  H2F  1X7RG1 
FW1  1  E  -  Q 
5  L  V  V 
13  Q  K  - 
19  R  -  T 
28  T  -  I 
CDR1  31  S  D  T 
33  A  Y  S 
35  S  -  N 
FW2  37  V  I  - 
CDR2  50  A  Y  Y 
51  I  -  T 
53  G  S  S 
54  S  R  - 
56  G  S  S 
57  S  T  T 
58  T  I  M 
61  G  A  A 
FW3  75  S  A  A 
78  T  S  S 
95  Y  -  F 
98  K  K  R 
folds can be formed by very different sequences.  It is likely 
that there are multiple ways different amino adds combine 
to form an antigen binding pocket with affinity for dsDNA 
antigenic epitopes.  Different idiotypic systems may display 
different motifs, and even within an idiotypic system different 
motifs may be present. The specificity of a particular amino 
acid will depend on the conformation and orientation of the 
protein backbone. Such observations may help explain the 
apparent acquisition of dsDNA binding in the VKl-encoded 
antibodies as a result of presumed somatic mutation despite 
no actual increase in the number of amino acids capable of 
contacting DNA. It is also important, however, to consider 
that DNA need not be the eliciting antigen and some amino 
acid substitution may be present to provide increased binding 
to an unidentified antigen. 
Based on the $107-U4 paradigm in which an antibacterial 
antibody, $107, underwent a single amino acid substitution 
in CDR1 and acquired binding to dsDNA, we have hypothe- 
sized that somatic mutation in vivo may also lead to DNA 
binding (39). In fact, all anti-dsDNA antibodies derived from 
individuals with SLE or lupus-prone mice that have been se- 
quenced so far appear to show somatic mutations (21, 22, 
40, 41). An analysis of the somatic mutations present in the 
expressed V region sequences can help determine if the anti- 
body response is antigen driven or is a consequence of poly- 
clonal activation, a major question in the study of the anti- 
DNA  response.  If  somatic  mutations  occur  randomly 
throughout the V region yielding a replacement to silent mu- 
tation ratio of 2.9:1,  then the antibodies may reflect B cell 
or T  cell polyclonal activation. If, however,  mutations are 
clustered in CDRs or if the R/S ratio in CDRs is >2.9:1, 
then antigen selection may play a role in expanding partic- 
ular B cells clones. The somatic mutations seen in some anti- 
dsDNA antibodies previously appear to lead to the acquisi- 
tion of DNA binding, and the unmutated germ line genes 
may be presumed to encode antibodies with little or no affinity 
for dsDNA.  For example,  the sequence  of the 2A4  anti- 
dsDNA antibody displays substitutions that lead to a more 
cationic antibody and one containing more putative DNA 
binding residues  in CDRs (18). 
We have performed an analysis of the presumed somatic 
mutations present in the 3I + light chains sequences reported 
here.  Because  all  the human VK genes have not yet been 
cloned and sequenced,  we attempted to isolate additional 
VK1 germline genes.  Of the five we sequenced,  two were 
1648  Antibodies  Bearing an Anti-DNA-associated  Idiotype Table  11.  (continued) 
Amino 
acid  56Pl  I-2a 
CDR1 
CDR2 
FW3 
32  Y  S 
33  A  P 
50  V  F 
53  Y  L 
54  D  E 
57  N  S 
58  K  Q 
68  F  L 
84  N  S 
98  R  S 
Amino 
acid  H16BR  III-3R 
FW1  9  stop  G 
CDR1  32  S  Y 
33  W  R 
35  H  S 
FW2  38  C  R 
42  E  G 
CDR2  50  D  N 
53  C  q 
FW3  83  V  M 
91  M  T 
92  T  A 
97  V  A 
pseudogenes. This finding is consistent with the reported high 
frequency of pseudogenes among human V region genes. We 
believe that all the 3I + light chains we have described have 
undergone somatic mutation. Studies on selected lines have 
shown the absence of CDR nucleotide sequences in the pa- 
tient's germline DNA, confirming the somatic acquisition 
of the CDR nucleotide sequences. It is clear, however, that 
the description of human V region genes is far from com- 
plete and that there is substantial allelic polymorphism in 
the population; therefore,  the mutational analysis remains 
speculative. When 3I § antibody genes are compared to the 
most homologous germline gene sequences available, they 
exhibit between 89%  and 96%  homology to the closest 
Vzl  germ line gene. Most of the Vzl-encoded 3I + anti- 
bodies display high R/S ratios in CDRs, suggesting substantial 
changes in antigen binding from their germ line-encoded 
counterparts. The analysis of these antibodies suggests that 
antigen selection drives the anti-DNA response, and it is pos- 
sible that the parental B cell may be initially triggered by 
an antigen only distantly related to DNA. II-1 exhibits 98% 
homology the nearest VK3 germline gene, and H2F exhibits 
Table  12.  Replacement  Mutations  in 3I + V~4 Sequences 
Amino 
acid  71-4  IC4 
FW1  6  Q  E 
29  S  I 
30  G  S 
CDR1  32  Y  F 
FW2  40  P  S 
CDR2  50  Y  T 
54  S  T 
FW3  73  T  M 
83  S  I 
85  V  L 
Amino 
acid  V71-2  2A4" 
FWl  16  E  q 
29  V  I 
CDR1  33  S  N 
FW2  43  P  A 
49  W  G 
CDR2  52  Y  R 
54  Y  D 
55  Y  T 
58  S  N 
59  T  I 
60  N  K 
FW3  73  V  I 
* Previously published data. 
98% homology to the single reported VK4 germline gene. 
For these two antibodies, the number of mutations is too 
small to speculate on whether they represent antigen sdec- 
tion or not. 
Our previous studies revealed that the V. gene utilization 
among this panel of EBV cell lines was quite heterogeneous 
(10).  Among the antibodies described here, four of the six 
V. families  are represented: V.1, V.3, V.4,  and VH5. The 
V.1 and V.3 families are the largest families,  including >30 
genes in each, whereas V.4 and V.5 are significantly smaller 
(6-10 genes and 2-3 genes, respectively) (42). The distribu- 
tion of V. gene usage by our panel of antibodies probably 
reflects on the size of each family and shows no restriction. 
The D  regions expressed by this group of lines are quite 
unusual. Only one of the eight lines newly reported, III-3R, 
expresses  an already identified D  gene. III-3R, III-2R, and 
1649  Manheimer-Lory  et al. Table  13.  Replacement Mutations  in 3I + I/'.5  Sequences 
Amino 
acid  251  II-1 
FW1  30  T  S 
CDR1  31  S  T 
34  T  I 
CDR.2  50  I  S 
51  I  V 
59  R  T 
FW3  75  S  C 
2A4 express D-D fusions,  a previously reported feature of 
autoantibodies (18, 32). The remaining six antibodies express 
D  segments of unknown origin. It is possible  that these D 
segments are highly diversified through somatic mechanisms 
or, alternatively, derive from germline Ds not yet described. 
J, usage is possibly restricted as seven of nine lines  utilize 
J,4. 
Most of the expressed V. genes are 89-98% homologous 
to previously published functional germ line genes, germ line 
pseudogenes, or rearranged genes derived from human fetal 
tissue (presumably germ line in sequence). It is apparent that 
the data presented in Table 9, showing replacement to silent 
substitution ratios for both FWs and CDRs, indicate that, 
similar to what is seen in the light chains, the heavy chains 
show strong conservation in FW sequences and high CDR 
substitution  rates.  However, unlike the light chains, there 
appear to be few arginine, asparagine,  and glutamine replace- 
ments, suggesting perhaps that DNA binding by these EBV 
lines is more a function of the light chain than the heavy chain. 
Van Es et al.  (43) described an IgG anti-DNA antibody 
from an EBV-transformed cell line derived from an SLE pa- 
tient encoded by VKIIIb and V.4 genes. Similar to the anti- 
V1,'i  ),  III-2R  0 POW~G~)NMFI)  PIIG(~GT  LV  IV5$ (OONl(-  JliS) 
R3.SH re:  SPL1YI"PVGYFOSIiGqGTLVTVSS  ( DONg-dtkl  ) 
..................................................... 
VH3  I|[-3R  6 B4MEIIM  FGF..$  PPFO  YMQQGT  LV'WS$ (0  UklK-  DX  P, 1. N-  JH4  ) 
1-2a  ~I~IE  LPF  D'ni~T LVTVS  S  ( DUNK-dH4  ) 
IK/~!  O  LT'T~  V'YILCa~  T  L  VXG'V  .T~ (OUI~-dlH4) 
H2F  OL~YDmGYFOYI~TLVTV~S(OgINK..JH4  ) 
................................................................ 
Wt4  It4  DSAID~F1) YMGQh'~  LVTV  q~ ( 9LINg-  dlH  4) 
2.44  o  szl~[ t ~',Pe,  Ar,  G~YGmW,  iGQGT'IVTVSSA(  ON2.  Le3-+.m6) 
VHS  11-1  ROY  NYGu  FIDPM~T LV'IVS$  ( DON  K-  ~1H4  ) 
bodies we report, this antibody appears to display more replace- 
ment mutations in CDRs  than in FW regions. Also,  like 
the antibodies we report, only one out of six presumed rephce- 
ment mutations in the heavy chain CDRs enriches for a poten- 
tial DNA binding amino acid, while the light chain replace- 
ment mutations enrich for arginine and asparagine. 
Our earlier studies on myeloma proteins showed that 3I + 
IgM antibodies are non-DNA binding, while the most 3I + 
IgG proteins bind to dsDNA (14). This observation on the 
association of DNA binding with the IgG isotype is in con- 
trast to studies on the EBV lines that we report here, where 
both  IgM  and  [gG antibodies bind DNA  although with 
varying affnities (10). While IgM myeloma proteins are often 
encoded by unmutated germ line genes, the IgM antibodies 
produced by our EBV lines are most probably mutated. This 
may be due to antigen selection for mutated IgMs or perhaps 
to a mechanism of hypermutation in SLE. 
These studies demonstrate some of the diffculties in struc- 
tural and genetic studies of antibody responses.  While our 
initial study of a single anti-dsDNA antibody suggested an- 
tigen selection and amino acid substitutions leading to an 
increased affinity for DNA, the analysis of the additional seven 
DNA binding antibodies reported here suggests that selec- 
tion for a more cationic antibody or for DNA binding residues 
in CDRs is not an obvious feature of all or even most of 
the antibodies. It is probable, however, that multiple forces 
act on the anti-DNA response and that the selection of the 
expressed repertoire is determined by forces such as idiotype 
as well as antigen, DNA,  or otherwise. The analysis  of a 
large number of human anti-DNA antibodies, including mul- 
tiple antibodies from individual patients,  shows that there 
is no single paradigm for explaining structural or molecular 
genetic features of these autoantibodies. The structural basis 
of the 3I idiotype cannot be localized from our amino acid 
sequences. Idiotypic determinants may well be conformation 
dependent and the accumulation of sequence data alone may 
be insuffcient for idiotype localization. The CDR1 domain 
of the light chain may well play a critical role in the binding 
of these antibodies to dsDNA, although this motif alone may 
not be sufficient. Site-directed mutagenesis of these antibody 
genes will be necessary to confirm this hypothesis. The anal- 
ysis of presumed somatic mutations in these antibodies is com- 
plex.  Human V  region genes have not been analyzed ex- 
tensively enough  to  make mutational  analysis  more than 
suggestive. Nevertheless, the preliminary analysis of these an- 
tibodies shows that mutations do not always lead to an in- 
crease in dsDNA binding residues or in antibody charge. More 
information on anti-DNA sequences and the human V re- 
gion germ line repertoire, including the extent of aUelic poly- 
morphism, is necessary in order to understand fully the origins 
of an autoantibody response and to elucidate the forces that 
determine the expressed antibody repertoire in SLE. 
Figure 9.  Junctional nucleotide sequences of heavy chains.  Several D 
regions could not be identified in the literature and are indicated as un- 
known (UNK). 
1650  Antibodies Beating an Anti-DNA-associated Idiotype This work was supported by National Institutes of Health grants AR-.32371, AI-10702, and National 
Cancer Institute grant  13330. Audrey Manheimer-Lory is a feLlow  of the Arthritis Foundation. Jessica 
B. Katz is supported by NIH training grant 5732 GM-7288. 
Address correspondence to Betty Diamond, Department of Microbiology and Immunology, Albert Ein- 
stein CoLlege  of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461. 
Received for publication 31 May 1991 and in revised  form 2 August 1991. 
l~el~nces 
1.  Winfield, J.B., I. Faiferman, and D. Koffer. 1977. Avidity of 
anti-DNA antibodies in serum and IgG glomerular eluates in 
patients with systemic  lupus erythematosus:  association  of  high 
avidity anti-native DNA antibody with glomerulonephritis. 
J.  Clin. Invest. 59:90. 
2.  Pearson,  L., and K.W. Light'foot,  Jr. 1981. Correlation of  DNA- 
anti-DNA  association rates with clinical activity in systemic 
lupus erythematosus. J. Immunol. 126:16. 
3.  Kallenberg, C.G.M., E.J. ter Borg., G. Horst,  F. Hummel, 
and PC. Limburg. 1989. Predictive  value  of  anti-double  stranded 
DNA antibody levels in SLE: a long term prospective study. 
Clin. Rheumatol, 8:49. 
4.  Raz, E., M. Brezis, E. Rosenmann, and D. Eilat. 1989. Anti- 
DNA antibodies bind directly to renal antigens and induce 
kidney dysfunction in the isolated perfused rat kidney.  J. Im- 
munol. 142:3076. 
5.  Tsao,  B.P., F.M. Ebling, C. Roman, N. Panosian-Sahakian,  K. 
Calame, and B.H. Hahn.  1990. Structural characteristics of 
the variable  regions  ofimmunoglobulin genes  encoding  a patho- 
genic autoantibody in routine lupus, f  Clin. Invest. 85:530. 
6.  Solomon, G., J. Schiffenbauer,  H.D. Keiser, and B. Diamond. 
1983. The use of monoclonal antibodies to identify shared idi- 
otypes on human antibodies to native  DNA from patients with 
systemic lupus erythematosus. Proc. Natl.  Acad. Sci. USA. 
80:850. 
7.  Diamond, B., and M.M. Schwartz. 1987. The glomerular im- 
mune deposits in patients with systemic  lupus erythematosus 
glomerulonephritis contain a common IgG idiotype. Kidney 
Int. 31:336. 
8.  Halpern, R., A. Davidson, A. Lazo, G. Solomon, R. Lahita, 
and B. Diamond. 1985. Familial  SLE: Presence of a cross reac- 
tive idiotype in healthy family  members..]. Clin. Invest. 76:731. 
9.  Grayzel, A., A. Solomon, C. Aranow, and B. Diamond. 1991. 
Antibodies elicited  by pneumococcal  antigens  bear an anti-DNA 
associated idiotype. J.  Clin. Invest. 87:842. 
10.  Manheimer-Lory, A.J., A. Davidson, D. Watkins, N. Han- 
nigan, and B. Diamond. 1991. Generation and analysis  ofclonal 
IgM and IgG producing B cell lines expressing an anti-DNA 
associated idiotype. J.  Clin. Invest. 87:1519. 
11. Tabor,  S., and C.C, Richardson. 1987. DNA sequence analysis 
with a modified  bacteriophage  T7 DNA polymerase.  Proc Natl. 
Acad, Sci. USA.  84:4767. 
12.  Sanger, F., S. Nicklen, and A.R. Coulson.  1977. DNA se- 
quencing with chain terminating inhibitors. Proa Natl. Acad. 
Sci. USA.  74:5463. 
13.  Williams, B.G., F.R. Blattner, S.R. Jaskunas, and M. Nomura. 
1977. Insertion of DNA carrying ribosomal protein genes of 
Escherichia coli into charon vector phages. J.  Biol. Chem. 
252:7344. 
14. Davidson, A., J.L. Preud'homme, A. Solomon, M.-d. Chang, 
S. Beede, and B. Diamond. 1987. Idiotypic analysis  ofmydoma 
proteins: anti-DNA activity of  monoclonal immunoglobulins 
bearing an SLE idiotype is more common in IgG than IgM 
antibodies, f  Immunol. 138:1515. 
15.  Weir, D.M. 1979. Handbook of Experimental Immunology, 
Vol. 1. Blackwell Scientific  Publications, London. 6.31-6.33. 
16. Blumenfeld,  O., A.J. Smith, andJ.J. Moulds. 1987. Membrane 
glycophorins  of  Dantu blood group erythrocytes.J. Biol. Chem. 
262:11864. 
17.  Kabat, E.A., T.T. Wu, M. Reid-MiUer, H.M. Perry, and K.S. 
Gottesman. 1987. Sequences of Proteins of Immunologic In- 
terest. U.S. Dept. of Health and Human Services, Wash. DC. 
14-29. 
18.  Davidson, A., A. Manheimer-Lory,  C. Aranow, K. Peterson, 
N. Hannigan, and B. Diamond.  1990. Molecular character- 
ization of a somatically mutated anti-DNA antibody bearing 
two SLE related idiotypes.  J.  Clin. Invest. 85:1401. 
19.  Seeman,  N.C., J.M. Rosenberg, and A. Rich. 1976. Sequence- 
specific recognition of  double helical nucleic acids by proteins. 
Proa Natl. Acad. Sci. USA.  73:804. 
20.  Eilat, D., D.M. Webster, and A.R. Rees. 1988. V regions of 
anti-DNA  and anti-KNA  autoantibodies from NZB/NZW 
F1 mice. J. Immunol. 141:1745. 
21.  Shlomchik, M.J.,  A.H.  Aucoin, D.S. Pisetsky, and M.G. 
Weigert. 1987. Structure and function of  anti-DNA autoanti- 
bodies derived from a single autoimmune mouse. Proa Natl. 
Acad. Sci. USA.  84:9150. 
22.  Behar, S.M., D.L. Lustgarten, S. Corbet, and M.D. Scharff. 
1990. Characterization of somatically mutated $107 VH11- 
encoded anti-DNA autoantibodies derived from autoimmune 
(NZB  x  NZW)F, mice. f  Exit Med. 173:731. 
23.  Radic, M.Z., A. MasceLli,  J. Erikson, H. Shun, and M. Weigert. 
1991.  Ig  H  and  L  chain  contribution  to  autoimmune 
specificities. J. Immunol. 146:176. 
24.  Bentley, D.L., and T.H. Rabbitts. 1983. Evolution ofimmu- 
noglobulin V genes: evidence indicating that recently dupli- 
cated human VK sequences have diverged by gene conversion. 
Cell. 32:181. 
25. Jaenichen, H.-K., M. Peck, W. Lindenmaier, N. Wildgruber, 
and H.G. Zachau. 1984. Composite human Vx genes and a 
model of their evolution. Nucleic Acids Res. 12:5249. 
26.  Meindl, A., H.-G. Klobeck, R. Ohnheiser, and H.G. Zachau. 
1990. The VK gene repertoire in the human germ line. Eur. 
f  Immunol. 20:1855. 
27.  Pech, M.N., H.-R. Jaenichen, H.-D. Pohlenz, P.S. Neumaier, 
H.-G. Klobeck, and H.G. Zachan. 1984. Organization and evo- 
lution of a gene cluster for human immunoglobulin variable 
regions of the kappa type. J. Mol. Biol. 176:189. 
1651  Manheimer-Lory  et al. 28.  Shlomchik,  M.J., A. Marshak-Rothstein,  L.B. Wolfowicz,  T.L. 
Kothstein, and M.G. Weigert. 1987. The role of clonal selec- 
tion and somatic mutation and autoimmunity. Nature (Lond.). 
328:805. 
29.  Chen, P.P., D.L. Robbins, F.R. Jirik,  T.J. Kipps, and D.A. 
Carson. 1987. Isolation and characterization of a light chain 
variable region gene for human rheumatoid factors.J. Exlx Med. 
166:1900. 
30.  Klobeck, H.-G., G.W. Bomkamm, G. Combriato, R. Mocikat, 
H.-D. Pohlenz, and H.G. Zachau. 1985. Subgroup  IV of  human 
immunoglobulin K light chains is encoded by a single germ- 
line gene. Nucleic Acids Res. 13:6515. 
31.  Hahn, B.H. 1982. Characteristics of pathogenic subpopula- 
tions of antibodies to DNA. Arthritis Rheum.  25:747. 
32.  Meek, K.D., C.A. Hasemann, and J.D. Capra. 1989. Novel 
rearrangements at the immunoglobulin D locus. Inversions  and 
fusions add to IgH somatic diversity.  J. Exp. Med. 170:39. 
33.  Ravetch,  J.V., U. Siebenlist, S. Korsmeyer,  T. Waldmann, and 
P. Leder. 1981. Structure of the human immunoglobulin/z 
locus: characterization of embryonic and rearranged J and D 
genes. Cell. 27:583. 
34.  Pascual, V., I. Randen, K. Thompson, M. Sioud, O. Forte, 
J. Natvig, and J.D. Capra. 1991. The complete nucleotide se- 
quences of the heavy  chain variable regions of six monospecific 
rheumatoid factors derived from EBV transformed B cells iso- 
lated from the synovial  tissue of patients with rheumatoid ar- 
thritis: further evidence that some autoantibodies are unmu- 
tared copies of germline genes. J.  Clin. Invest. 85:1603. 
35.  Sanz, I., P. Casali,  J.W. Thomas, A.L. Notkins, andJ.D. Capra. 
1989.  Nucleotide  sequences of  eight  human  natural  V. 
regions reveal apparent restricted use of V. families.  J. Im- 
munol. 142:4054. 
36. Shen, A., C. Humphries, P. Tucker, and F. Blattner. 1987. 
Human heavy-chain  variable region gene family  nonrandomly 
rearranged in familial  chronic lymphocytic  leukemia.  Pro~ Natl. 
Acad. Sci. USA.  84:8563. 
37.  Hoch, S., and J. Schwaber. 1987. Identification and sequence 
of the V, gene elements encoding a human anti-DNA anti- 
body. J. Imrnunol. 139:1689. 
38.  O'Keefe, T.L., S. Bandyopadhyay,  S.K. Datta, and T. Imanishi- 
Karl. 1990. V region sequences of an idiotypicaUy  connected 
family of pathogenic anti-DNA  autoantibodies. J. Imraunol. 
144:4275. 
39.  Diamond, B., and M.D. Scharff. 1984. Somatic mutation of 
the T 15 heavy chain gives rise to an antibody with autoanti- 
body specificity.  Proc Natl.  Acad. Sci. USA.  81:5841. 
40.  Shlomchik,  M., M. MasceUi,  H. Shah, M.Z. Radic,  D. Pisetsky, 
A. Marshak-Rothstein, and M. Weigert. 1990. Anti-DNA an- 
tibodies from autoimmune mice arise  by donal expansion and 
somatic mutation. J. Ext~ Med. 171:265. 
41.  Marion,  T.N.,  A.L.M.  Bothwell,  D.E. Briles, and  C.A. 
Janeway, Jr. 1989. IgG anti-DNA  autoantibodies within an 
individual autoimmune mouse are the products of clonal se- 
lection. J. Immunol.  142:4269. 
42.  Berman,  J.E., S.J. Mellis, K. Pollock, C.L. Smith, H. Suh, 
B. Heinke, C. Kowal, U. Surti, L. Chess, C. Cantor, and F.W. 
Alt.  1988. Content and organization of the human Ig V, 
locus: definition of three new V. families and linkage to the 
Ig C, locus. EMBO (Eur. Mol. Biol. Orsan.) J.  3:727. 
43.  Van Es, J.H., F.H.J. Gmelig Meyling,  W.R.M. Van De Akker, 
H. Aastoot, K.H.W.M. Derksen, and T. Logtenberg. 1991. 
Somatic mutations in the variable  regions of  a human IgG anti- 
double stranded DNA autoantibody suggest a role for antigen 
in the induction of systemic  lupus erythematosus.J. Extx Med. 
173:461. 
1652  Antibodies  Bearing an Anti-DNA-associated  Idiotype 